Scandion Oncology announces that the Clinical Trial Application for a pancreatic cancer study with chemotherapy and SCO-101 has been submitted to the Danish Medicines Agency and the Ethical Committee.
Scandion Oncology A/S (“Scandion Oncology”) is pleased to announce that a Clinical Trial Application (CTA) has been submitted to the Danish Medicines Agency and the Ethical Committee. A response is expected within 60 days.Pancreatic cancer is one of the most aggressive cancer forms with almost 75% of patients presenting with chemotherapy resistant disease. Due to this resistance, very few pancreatic cancer patients will be long-term survivors. A drug that reverses chemotherapy resistance in pancreatic cancer and other cancer forms will obviously have a significant commercial potential.